Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 14/20 | 0.65 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | GYS1 | P13807 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796639 | 0.93 | ARF6 (0.67) | ARF6PLATGYS1KCNQ3KCNQ2 | |
| SCHEMBL20796640 | 0.92 | ARF6 (0.56) | ARF6PLATGYS1KCNQ3KCNQ2 | |
| SCHEMBL20796479 | 0.91 | ARF6 (0.64) | ARF6PLATGYS1PSDSMN1; SMN2 | |
| SCHEMBL20796480 | 0.89 | ARF6 (0.70) | ARF6PLATGYS1PSDSMN1; SMN2 | |
| SCHEMBL20796538 | 0.83 | ARF6 (0.68) | ARF6GYS1 | |
| SCHEMBL20796637 | 0.83 | ARF6 (0.55) | ARF6PLATGYS1 | |
| SCHEMBL20796638 | 0.82 | ARF6 (0.54) | ARF6GYS1 | |
| SCHEMBL20796477 | 0.82 | ARF6 (0.67) | ARF6GYS1PSD | |
| SCHEMBL20796478 | 0.80 | ARF6 (0.71) | ARF6PLATGYS1 | |
| SCHEMBL20796482 | 0.79 | ARF6 (1.00) | ARF6PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414442-B2 | ARF6 inhibitors and related methods | NAVIGEN, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. | 2021-01-21 | — | — | US | disclosed |
| WO-2019040499-A2 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | ARF6, ARF1, ARF5 | ARF6 1/4885PLAT 621/4885GYS1 4665/4885 |
| US-11414442-B2 | ARF6 inhibitors and related methods | ARF6, ARF1, ARF5 | ARF6 1/4885PLAT 621/4885GYS1 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.